Close

Press Releases

Shilpa Biologicals Pvt Ltd signs strategic development partnership with mAbTree Biologics AG for a novel immuno-oncology asset

Basel Switzerland, and Karnataka India:  mAbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd. (a fully owned subsidiary of Shilpa Medicare Limited) for its novel biologic asset for immuno-oncological applications. Under the terms of the strategic...

Sirio Launches Global Research Institute for Longevity Studies [SIA]

Research Institute to advance nutraceutical product development across four core research areas SIRIO Pharma (SIRIO) – the global nutraceutical contract development and manufacturing organization (CDMO) – announces the launch of the Sirio Institute for Anti-Ageing (SIA) at the 2025 Boao Health Food Science Conference and...

Shilpa Launches ‘hybrid CDMO’ at DCAT

Shilpa Medicare launches its new full service ‘hybrid’ CDMO at DCAT 2025. The newly formed CDMO will see Shilpa serve both small and large molecules customers as well as peptides – with oncology a particular therapeutic specialism. In addition to offering...

CordenPharma Expands Peptide Platform with >€500m Greenfield Facility Construction in the Basel Region of Switzerland

CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities across Europe and the US. In Switzerland, CordenPharma will invest >€500m to construct...

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

The Purification & Filtration division manufactures filters and membranes for biopharmaceutical and medical technologies, microelectronics, food and beverage goods, and drinking water. It employs over 2,500 people worldwide and has locations in the Americas, Europe, the Middle East, Africa,...

LINDIS Biotech Partners with Celonic for Production and Commercial Supply of Catumaxomab

LINDIS Biotech has received EMA Marketing Authorisation for catumaxomab, making it the only medicine licensed for the targeted and cancer-directed therapy of malignant ascites. Celonic Group will produce catumaxomab for commercial use. Catumaxomab will be manufactured at Celonic's...

Andelyn Biosciences Expands AAV Curator Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and...

COLUMBUS, OH - Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has expanded its AAV Curator™ Platform offering and License Agreement with the Broad Institute of MIT and Harvard to include...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read